Platforms for Performance: Clinical Dashboards to Improve Quality and Safety 2011 Midyear Clinical Meeting
|
|
- Pierce Pierce
- 5 years ago
- Views:
Transcription
1 Improving Mental Health Outcomes in Veterans Through Dashboard Technology Learning Objectives 1. Describe VA Academic Detailing 2. Show how an increase in metabolic monitoring and a decrease in off-label use of antipsychotics can be achieved and sustained Amy Furman, Pharm.D. Mental Health Data Manager VA Sierra Pacific Network (V21) VA Desert Pacific Network (V22) 3. Demonstrate the VISN 21/22 Academic Detail Dashboard products and tools 2 What is VA Academic Detailing? Academic Educator for Pilot Program Clinical mental health pharmacists Work with mental health providers to provide increased access to current literature Do you have experience working with an Academic Detailing Program? 1. Yes Our Purpose Provide evidence based non-commercial biased educational outreach to patients and providers More appropriately utilize healthcare system resources AIM Using clinical pharmacists as academic educators, partner with MH providers to improve veteran health outcomes for patients using mental health medications by July No 3 4 Opportunities to Improve High rate of poly-pharmacy in MH based on 5 drug review Poor coordination of care between MH and PC Low rates of metabolic monitoring in MH Low rates of clozapine and risperidone use High off-label use of Atypical Antipsychotics High dose Low dose Dementia PTSD Which topic is of most interest to you? 1. Improving the monitoring of metabolic syndrome and reducing related risks 2. Fostering greater use of clozapine in refractory patients diagnosed with schizophrenia 3. Decreasing the off-label use of antipsychotics 4. Other 5 6 Page 1 of 7
2 Structured Educational Outreach Visit Process Topic Key Message Tools Results (metrics) Every message (principle) has tools and a specific metric Cannot determine success of a message without metrics Tools should reinforce message and promote results Metabolic Monitoring Weight, BP, BG, and lipids should be monitored at least annually Consider alternative agents minimize metabolic risk Select agents with more favorable metabolic profiles Key Messages Off Label Use Clozapine Utilization Explore alternate therapeutic FGA and SGA have similar options for patients with PTSD, efficacy as initial therapy Dementia and Sleep Optimize monotherapy before using multi drug therapy Evaluate alternate treatment options before using higher than labeled dosing Clozapine is superior for treatment resistant schizophrenia Efficacy and safety of high dose antipsychotics has not been demonstrated 7 8 Tools Poster to Increase Patient Involvement Evaluate Clinics for Equipment Provider Educational Materials Patient Educational Handouts Letters to the Patient Posters Promoting Patient Involvement Quick Reference Cards for Providers Mental Health Clinical Dashboards Actionable Reports 9 1 Mental Health Dashboards Mental Health Dashboard Benefits Leverages local, regional and national data Daily data extraction from data warehouse Analyzes entire mental health patient population Information can be used to: Track performance administratively Make clinical interventions to improve patient outcomes Page 2 of 7
3 Metabolic Monitoring Dashboard Metabolic Monitoring Dashboard and Reports Drill Down Options Making a Difference: Provider Level Data Link to a report of patients requiring action Upcoming Appointments Report Drill to Detail Entire Panel Report Page 3 of 7
4 Post Traumatic Stress Disorder Evidence Based Prescribing Dashboard and Reports Re examining our use of Antipsychotics in PTSD, Risk vs Benefit, Are there candidates to do a trial off of antipsychotic 19 2 Risperidone Not Effective in PTSD What about all the other ones Krystal Study JAMA August 211 (1) No difference than placebo in Cognitive Global Impression scale Despite its widespread use, risperidone (Risperdal) is not effective in patients with combat-related PTSD, according to the results of a multicenter VA study. Risperdal, an antipsychotic, has been found successful in treating schizophrenia, bipolar disorder, and some of the symptoms of autistic disorder. The drug acts primarily on the dopaminergic and serotonergic systems. Physicians have been using risperidone and other second-generation antipsychotics as adjunctive therapy for PTSD patients who do not respond to selective serotonin reuptake inhibitors (Saris) believing that it could improve the hyperarousal and re-experiencing symptoms of PTSD US Medicine Report August 211 Examine Opportunities for Interventions Off Label Indications $1,337,68 annualized cost / 2352 patients Which Antipsychotics are used? VISN Patients All Patients Patients >= 12 Fills Avg Cost/ Patient $ $ 1, DrugName WithoutDose Patients Fills Total Cost QUETIAPINE $ 63, OLANZAPINE $ 328, ARIPIPRAZOLE $ 32, ZIPRASIDONE $ 62,565.2 RISPERIDONE $ 31, PERPHENAZINE $ 6, CHLORPROMAZINE $ THIOTHIXENE 3 26 $ HALOPERIDOL $ Consider Role of AP in Off Label Indications (PTSD, Dementia, Sleep) Non Evidence Based Prescribing Report Do you currently have a method to evaluate adherence? Upcoming Appointments 1. Yes 2. No Sum of Day s Supply Received Sum of Day s Elapsed = Adherence Page 4 of 7
5 PTSD with an Antipsychotic and No Antidepressant Report Weighing the Risks and Benefits If I am already obese, does it bother me to be put on a drug at risk of causing weigh gain and cardiac risk given I am struggling to get the weight off, and I m trying to get my depression symptoms under control? As a patient would I choose Diabetes over a good night sleep? Reducing Risk Increasing Benefit Clozapine Dashboard Clozapine Report Allows you to select: Station Mental Health Provider Distance from Medical Center 29 3 Page 5 of 7
6 Total Hits April July 211 Total Hits By VISN VISN 21 VISN /1/211 5/1/211 6/1/211 7/1/211 Apr-11 May-11 Jun-11 Jul-11 Hits By Report Clozapine Metabolic Appointment Metabolic Entire Panel Metabolic Prescriber Appointment Metabolic Prescriber Entire Panel Off Label Appointment Off Label Entire Panel Unassigned Patients Results Interim analysis completed October 21 through February /1/211 5/1/211 6/1/211 7/1/ e FY21 to FY211 nterim Analysis) % from Baselin (5 Month In MEASURE: Annual Metabolic Monitoring % Change FY21 to FY211 Weight Blood Pressure Glucose/A1c HDL Triglycerides VISN VISN Combined VISN 21/ % 16% 14% 12% 1% 8% 6% 4% 2% % % Patients Receiving Two or More Antipsychotics PolyPharmacy Impact Pre Intervention Post Intervention * P<.1 * p<.1 * P<.1 VISN 21 VISN 22 Combined V21/V22 36 Page 6 of 7
7 14% 12% 1% Patients Using Low Dosed Antipsychotics Chronically (>9 Days) For Sleep, Dementia & Other Off labeled Indications Pre Intervention Post Intervention Summary of Interim Results: Metabolic Risk Reduction Significant improvements in monitoring was found for combined analysis VISN 21/22 by working with individual facilities to address site barriers. 8% 6% * P <.1 * P <.1 * P <.1 Metabolic control has a longer lag time to impact with the both prescribing changes of antipsychotics and treatment of patients with metabolic abnormalities. 4% 2% % VISN 21 VISN 22 Combined V21/V22 Gap in care between PCP and patient management goals, will be difficult to attain metabolic control for % of the population. 38 Conclusions Mental Health Dashboards and Academic Detailers collaborative model demonstrated early impact on prescribing practices in VISN 21/22. Patient clinical outcomes require a longer duration for measurement period to see the total t impact of the provider behavior change. What OPPORTUNITIES Do You See? How do we Make IT happen? Further evaluation is needed to determine which modalities of this educational model are most effective References 1. Edersheim, JG. Off-label prescribing. Psychiatric Times volume 26, no. 4 accessed at (June 7, 29). 2. O Brien MA, et al. Educational outreach visits: effects on professional practice and health care outcomes (Review). The Cochran Collaborative, A template for establishing and administering prescriber support and education programs: A collaborative, service-based approach for achieving maximum impact. A report by Prescription Policy Choice s Academic Detailing Planning Initiative, Siegel, A et al. Academic Detailing to Improve Antihypertensive Prescribing Patterns. Am J Hyperten 23; 16: Stender M et al. Medical resource use among patients treated for bipolar disorder: a retrospective, cross sectional, descriptive analysis. Clin Ther 22; 24 (1) Gou JJ et al. Risk of diabetes mellitus associated with atypical antipsychotic use among patients with bipolar disorder: A retrospective, population based, case-control study. J Clnic Psychiatry 26; 67(7) Jing et al. Healthcare costs associated with treatment of bipolar disorder using a mood stabilizer plus adjunctive ripiprazole, quetiapine, risperidone, olanzapine or ziprasidone. J Med Economics 29; 12(2): Gibson T, et al Cost Burden of Treatment Resistance in Patients with Depression AJMC 21 16, (5); Rush AJ, et al Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D Report. Am J Psychiatry 26; 163(11); Krystal JH, et al. Adjunctive risperidone treatment for antidepressant-resistant symptoms of chronic military service-related PTSD: a randomized trial. JAMA 211;36(5): Page 7 of 7
Michael J. Bailey, M.D. OptumHealth Public Sector
Michael J. Bailey, M.D. OptumHealth Public Sector LIHP Quality Charter To ensure the quality of care delivered to enrollees in San Diego County Assistance Programs, such as County Medical Services (CMS)
More informationKelly E. Williams, Pharm.D. PGY2 Psychiatric Pharmacy Resident April 16,2009
Kelly E. Williams, Pharm.D. PGY2 Psychiatric Pharmacy Resident April 16,2009 List the antipsychotics most often prescribed Compare and contrast the use and adverse effects experienced in the pediatric
More informationPharmacy Medical Necessity Guidelines: Antipsychotic Medications
Pharmacy Medical Necessity Guidelines: Antipsychotic Medications Effective: July. 1, 2016 Prior Authorization Required Type of Review Care Management Not Covered Type of Review Clinical Review Pharmacy
More informationFL Medicaid Drug Therapy Management Program for Behavioral Health Monitoring for Safety and Quality
FL Medicaid Drug Therapy Management Program for Behavioral Health Monitoring for Safety and Quality April 23, 2014 Pensacola, FL Presentation Objectives To briefly describe the program and how its components
More informationUse of Anti-Psychotic Agents in Irish Long Term Care Residents with Dementia
Use of Anti-Psychotic Agents in Irish Long Term Care Residents with Dementia Aine Leen, Kieran Walsh, David O Sullivan, Denis O Mahony, Stephen Byrne, Margaret Bermingham Pharmaceutical Care Research Group,
More informationDIABETES ASSOCIATED WITH ANTIPSYCHOTIC USE IN VETERANS WITH SCHIZOPHRENIA
DIABETES ASSOCIATED WITH ANTIPSYCHOTIC USE IN VETERANS WITH SCHIZOPHRENIA Fran Cunningham, Pharm.D. Department of Veterans Affairs* University of Illinois at Chicago Bruce Lambert, Ph.D. University of
More informationMental Health Medicines Management Pilot. Community Pharmacy. High Dose Antipsychotic Screening, Education & Advice Service
Mental Health Medicines Management Pilot Community Pharmacy High Dose Antipsychotic Screening, Education & Advice Service Approved Version 1 Date of First Issue Review Date Date of Issue Author / Contact
More informationMeasure #383 (NQF 1879): Adherence to Antipsychotic Medications For Individuals with Schizophrenia National Quality Strategy Domain: Patient Safety
Measure #383 (NQF 1879): Adherence to Antipsychotic Medications For Individuals with Schizophrenia National Quality Strategy Domain: Patient Safety 2016 PQRS OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY
More informationAntipsychotic Prior Authorization Request
Antipsychotic Prior Authorization Request Commonwealth of Massachusetts MassHealth Drug Utilization Review Program P.O. Box 2586, Worcester, MA 01613-2586 Fax: 1-877-208-7428 Phone: 1-800-745-7318 MassHealth
More informationMeasure #383 (NQF 1879): Adherence to Antipsychotic Medications For Individuals with Schizophrenia National Quality Strategy Domain: Patient Safety
Measure #383 (NQF 1879): Adherence to Antipsychotic Medications For Individuals with Schizophrenia National Quality Strategy Domain: Patient Safety 2017 OPTIONS F INDIVIDUAL MEASURES: REGISTRY ONLY MEASURE
More informationGeodon for anxiety and depression
When drugs like carbamazepine or cisapride are taken with Geodon, drug interactions can potentially occur. This emedtv page lists other drugs that may lead to Geodon. 8-2-2017 Find a comprehensive guide
More informationAre Two Antipsychotics Better Than One?
Are Two Antipsychotics Better Than One? Lauren Hanna, M.D and Delbert Robinson, M.D. Northwell Health National Council for Behavioral Health Montefiore Medical Center Northwell Health New York State Office
More informationAdvancements in the Assessment of Medication Adherence: A Panel Discussion and Case Study. Finding Clarity in the Midst of Uncertainty
Advancements in the Assessment of Medication Adherence: A Panel Discussion and Case Study Finding Clarity in the Midst of Uncertainty Agenda Medication adherence in serious mental illness Consequences
More informationAtypical Antipsychotic Use for the Behavioural and Psychological Symptoms of Dementia in the Elderly
Overall Comprehensive Research Plan: Atypical Antipsychotic Use for the Behavioural and Psychological Symptoms of Dementia in the Elderly October 9, 2014 30 Bond Street, Toronto ON, M5B 1W8 www.odprn.ca
More informationMr. E, age 37, has a 20-year history
Antipsychotics for obsessive-compulsive disorder: Weighing risks vs benefits Taylor Modesitt, PharmD, Traci Turner, PharmD, BCPP, Lindsay Honaker, DO, Todd Jamrose, DO, Elizabeth Cunningham, DO, and Christopher
More informationPresented by Rengena Chan-Ting, DO, CMD, FACOI Jenna D. Toniatti, PharmD
Presented by Rengena Chan-Ting, DO, CMD, FACOI Jenna D. Toniatti, PharmD Define BPSD and review the spectrum of associated symptoms Review pharmacologic and non-pharmacologic treatments for BPSD Evaluate
More informationVeterans Health Administration Pharmacy Benefits Management Academic Detailing Services
Veterans Health Administration Pharmacy Benefits Management Academic Detailing Services Melissa Christopher, Pharm.D. National Director, Academic Detailing Services VACO PBM San Diego, California USA Academic
More informationPharmacy Medical Necessity Guidelines: Antipsychotic Medications
Pharmacy Medical Necessity Guidelines: Effective: October 1, 2016 Prior Authorization Required Type of Review Care Management Not Covered Type of Review Clinical Review Pharmacy (RX) or Medical (MED) Benefit
More informationClass Update: Oral Antipsychotics
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More informationSupplementary Online Content
Supplementary Online Content Huybrechts KF, Hernández-Díaz S, Patorno E, et al. Antipsychotic use in pregnancy and the risk for congenital malformations. JAMA Psychiatry. Published online August 17, 2016.
More informationIOWA MEDICAID DRUG UTILIZATION REVIEW COMMISSION 100 Army Post Road (515)
IOWA MEDICAID DRUG UTILIZATION REVIEW COMMISSION 100 Army Post Road (515) 974-3131 -866-626-0216 Brett Faine, Pharm.D. Larry Ambroson, R.Ph. Casey Clor, M.D. Professional Staff: Mark Graber, M.D., FACEP
More informationRexulti (brexpiprazole)
Market DC Rexulti (brexpiprazole) Override(s) Approval Duration Prior Authorization 1 year Quantity Limit *Indiana see State Specific Mandates below *Maryland see State Specific Mandates below *Virginia
More informationOpioid Safety Initiative. Thomas Emmendorfer, PharmD Deputy Chief Consultant Pharmacy Benefits Management (PBM) Services
Opioid Safety Initiative Thomas Emmendorfer, PharmD Deputy Chief Consultant Pharmacy Benefits Management (PBM) Services 1 2 Opioid Safety Initiative (OSI) Overdose Education and Naloxone Distribution (OEND):
More informationProposed Changes to Existing Measure for HEDIS : Adherence to Antipsychotic Medications for Individuals With Schizophrenia (SAA)
Proposed Changes to Existing Measure for HEDIS 1 2020: Adherence to Antipsychotic Medications for Individuals With Schizophrenia (SAA) NCQA seeks comments on proposed modifications to the HEDIS Health
More informationTable of Contents. 1.0 Policy Statement...1
Division of Medical Assistance General Clinical Policy No. A-6 Table of Contents 1.0 Policy Statement...1 2.0 Policy Guidelines...1 2.1 Eligible Recipients...1 2.1.1 General Provisions...1 2.1.2 EPSDT
More informationDebra Brown, PharmD, FASCP Pharmaceutical Consultant II Specialist. HMS Training Webinar January 27, 2017
Debra Brown, PharmD, FASCP Pharmaceutical Consultant II Specialist HMS Training Webinar January 27, 2017 1 Describe nationwide prevalence and types of elderly dementia + define BPSD Define psychotropic
More informationPolicy Evaluation: Low Dose Quetiapine Safety Edit
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University 500 Summer Street NE, E35, Salem, Oregon 97301 1079 Phone 503 947 5220 Fax 503
More informationImplementation of Performance Improvement Projects
Implementation of Performance Improvement Projects Mary Marlatt-Dumas, Quality Manager, NMRE, Region 2 Diane L. Bennett, QI Coordinator/Compliance Officer, NorthCare Network, Region 1 Bill Phelps, Quality
More informationPHARMACY BENEFIT UPDATE Spring 2009 Issue. Preferred Drug List (PDL) News. Drugs with Positive Change in PDL Status
Department of Health and Human Services MaineCare Services 442 Civic Center Drive # 11 State House Station Augusta, Maine 04333-0011 Tel: (207) 287-2674; Fax: (207) 287-2675 TTY: 1-800-423-4331 PHARMACY
More informationOutpatient use of Atypical Antipsychotic Agents in the Pediatric Population Years
Outpatient use of Atypical Antipsychotic Agents in the Pediatric Population Years 2004-2008 Laura Governale, Pharm.D., MBA Team Leader, Drug Utilization Data Analyst Hina Mehta, Pharm.D. Drug Utilization
More informationPORT, 2009 Spain, 2009 Malaysia, 2009 Singapore, 2009 BAP, 2011 WFSBP, 2012 SIGN, 2013 Harvard NICE RANZCP, 2016
Appendix 3. Comparison of recommendations from clinical practice guidelines. Data extracted in relation to key health questions that are relevant to a clinician adopting an algorithmic approach to the
More informationTreatment of Schizophrenia
Treatment of Schizophrenia Conduct comprehensive assessment and use measurement-based care as found in the Principles of Practice (review pages 4-7). Most importantly assess social support system (housing,
More informationRestrained use of antipsychotic medications:
Balanced information for better care Restrained use of antipsychotic medications: Rational management of irrationality These drugs are commonly prescribed in conditions for which there is little evidence
More informationAbbreviated Class Review: Long-Acting Injectable Antipsychotics
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35, Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More informationSlide 1. Slide 2. Slide 3. About this module. About this module. Antipsychotics: The Essentials Module 5 A Primer on Selected Antipsychotics
Slide 1 Antipsychotics: The Essentials Module 5 A Primer on Selected Antipsychotics Flavio Guzmán, MD Slide 2 About this module 13 antipsychotics will be studied 3 first generation antipsychotics 10 second
More informationAbbreviated Class Review: Long-Acting Injectable Antipsychotics
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35, Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More informationObjectives. Antipsychotics 7/25/2016. LeadingAge Florida 53rd Annual Convention & Exposition
Reducing the Use of Antipsychotics in Long Term Care Communities Alan W. Obringer RPh, CPh, CGP Executive Director Senior Care Pharmacy Objectives Recognize the clinical evidence for the need to change
More informationFirst Steps: Considering Clozapine for your Patients
First Steps: Considering Clozapine for your Patients The Care Transitions Network National Council for Behavioral Health Montefiore Medical Center Northwell Health New York State Office of Mental Health
More informationPromoting and Monitoring Evidenced-Based Antipsychotic Prescribing Practices in Children and Adolescents: Florida Medicaid Initiatives
Promoting and Monitoring Evidenced-Based Antipsychotic Prescribing Practices in Children and Adolescents: Florida Medicaid Initiatives Mary Elizabeth Jones, Pharm BSc, RPh Senior Pharmacist AHCA Pharmacy
More informationAssessing Conformance to Medication Treatment Guidelines for Schizophrenia in a Community Mental Health Center (CMHC)
Community Mental Health Journal, Vol. 39, No. 6, December 2003 ( 2003) Assessing Conformance to Medication Treatment Guidelines for Schizophrenia in a Community Mental Health Center (CMHC) Mona Goldman,
More informationWorking with Clients Experiencing a First Episode of Psychosis: Considerations for Prescribers
Working with Clients Experiencing a First Episode of Psychosis: Considerations for Prescribers Tuesday, February 23, 2016 2pm Eastern Delbert Robinson, M.D. Professor of Psychiatry and Molecular Medicine
More informationThe Pediatric Behavioral Health Medication Initiative September 2016
The Pediatric Behavioral Health Medication Initiative Neha Kashalikar, PharmD Clinical Consultant Pharmacist UMass Medical School Clinical Pharmacy Services Background Several studies investigated trends
More informationRecent Advances in the Antipsychotic Treatment of People with schizophrenia. Robert W. Buchanan, M.D.
Recent Advances in the Antipsychotic Treatment of People with schizophrenia Robert W. Buchanan, M.D. Antipsychotic medications are the primary class of drugs used in the pharmacological treatment of schizophrenia.
More informationAntipsychotics in Bipolar
Use of Second-Generation Antipsychotics in Bipolar Disorder: A Practical Guide Flavio Guzman, MD Editor Psychopharmacology Institute This practical guide is an update on the use of second-generation antipsychotics
More informationThe chronic nature of schizophrenia is a major contributor
At a Glance Practical Implications p108 Author Information p 115 Full text and PDF www.ajpblive.com Schizophrenia Costs for Newly Diagnosed Versus Previously Diagnosed Patients Treatment Costs Leslie S.
More informationOut with the Old In with the New: Novel, Neuroscience-Based Re-Classification of Psychiatric Medications
Program Outline Out with the Old In with the New: Novel, Neuroscience-Based Re-Classification of Psychiatric Medications Rajiv Tandon, MD Professor of Psychiatry University of Florida College of Medicine
More informationThe 2009 Schizophrenia PORT Psychopharmacological Treatment Recommendations and Summary Statements
Schizophrenia Bulletin vol. 36 no. 1 pp. 71 93, 2010 doi:10.1093/schbul/sbp116 Advance Access publication on December 2, 2009 The 2009 Schizophrenia PORT Psychopharmacological Treatment Recommendations
More informationHearts and Minds An ECG Update. Tuesday 18 th November The Met Hotel, Leeds
Hearts and Minds An ECG Update Tuesday 18 th November The Met Hotel, Leeds Ashleigh Bradley Specialist Clinical Pharmacist for Mental Health and Lithium Clinic Airedale NHS Foundation Trust Introduction
More informationPharmacy Medical Necessity Guidelines: Atypical Antipsychotic Medications. Effective: December 12, 2017
Pharmacy Medical Necessity Guidelines: Effective: December 12, 2017 Prior Authorization Required Type of Review Care Management Not Covered Type of Review Clinical Review Pharmacy (RX) or Medical (MED)
More informationMany patients with schizophrenia
Long-Term Antipsychotic Polypharmacy in the VA Health System: Patient Characteristics and Treatment Patterns Julie A. Kreyenbuhl, Pharm.D., Ph.D. Marcia Valenstein, M.D., M.S. John F. McCarthy, Ph.D.,
More informationIntroduction. Objectives. Psychotropic Medications & Cardiometabolic Risk
Psychotropic Medications & Cardiometabolic Risk Sam Ellis, PharmD, BCPS, CDE Associate Professor University of Colorado School of Pharmacy Introduction Second GenerationAntipsychotics (SGA) first FDA approved
More informationMore than We Bargained For: Metabolic Side Effects of Antipsychotic Medications
More than We Bargained For: Metabolic Side Effects of Antipsychotic Medications Michael D. Jibson, MD, PhD Professor of Psychiatry University of Michigan Disclosure In the past 12 months I have received
More informationOptima Health. Schizophrenia. Next Review Date 9/19
Optima Health Schizophrenia Guideline History Original Approve Date 04/01 Review/Revise 3/05, 12/06, 09/08, 11/08, Dates 11/10, 7/11, 7/13, 7/15, 9/17 Next Review Date 9/19 These Guidelines are promulgated
More informationObjectives. Pre Discussion Question #2. Disparity in Care Demographics
Objectives Implementation of a pharmacist driven metabolic monitoring protocol for second generation antipsychotics (SGAs) Jonathan Willett, PharmD PGY 1 Pharmacy Practice Resident Chickasaw Nation March
More informationPharmacy Medical Necessity Guidelines: Atypical Antipsychotic Medications. Effective: February 20, 2017
Pharmacy Medical Necessity Guidelines: Effective: February 20, 2017 Prior Authorization Required Type of Review Care Management Not Covered Type of Review Clinical Review Pharmacy (RX) or Medical (MED)
More informationAntipsychotics Prior Authorization Criteria for Louisiana Fee for Service and MCO Medicaid Recipients
Antipsychotics Prior Authorization Criteria for Louisiana Fee for Service and MCO Medicaid Recipients Preferred Agents (Oral) a Amitriptyline/Perphenazine (Generic) Aripiprazole Tablet (Generic) b Chlorpromazine
More informationEffective Health Care Program
Comparative Effectiveness Review Number 43 Effective Health Care Program Off-Label Use of Atypical Antipsychotics: An Update Executive Summary Background Antipsychotics medications are approved by the
More informationPharmacy Medical Necessity Guidelines: Antipsychotic Medications
Pharmacy Medical Necessity Guidelines: Effective: April 1, 2018 Prior Authorization Required Type of Review Care Management Not Covered Type of Review Clinical Review Pharmacy (RX) or Medical (MED) Benefit
More informationSchizophrenia, a devastating chronic. Treatment Adherence Associated With Conventional and Atypical Antipsychotics in a Large State Medicaid Program
Treatment Adherence Associated With Conventional and Atypical Antipsychotics in a Large State Medicaid Program Joseph Menzin, Ph.D. Luke Boulanger, M.A. Mark Friedman, M.D. Joan Mackell, Ph.D. John R.
More informationHandout for the Neuroscience Education Institute (NEI) online activity: First-Episode Schizophrenia: Setting the Stage for Successful Outcomes
Handout for the Neuroscience Education Institute (NEI) online activity: First-Episode Schizophrenia: Setting the Stage for Successful Outcomes Learning Objectives Initiate low-dose antipsychotic medication
More informationAntipsychotics. Something Old, Something New, Something Used to Treat the Blues
Antipsychotics Something Old, Something New, Something Used to Treat the Blues Objectives To provide an overview of the key differences between first and second generation agents To an overview the newer
More informationClozapine Case 6: Half-Life Jose de Leon, MD
Clozapine Case 6: Half-Life 1-16-16 Jose de Leon, MD 6. Clozapine Case 6 J Clin Psychopharmacol 1996;16:193-4. http://www.ncbi.nlm.nih.gov/pubmed/8690839 Educational Objectives At the conclusion of this
More informationDisclosure Statement. A Rational Approach to Psychopharmacology. Goals 10/28/2013
A Rational Approach to Psychopharmacology Disclosure Statement Full time employed physician with MaineGeneral Medical Center in Waterville and Augusta No conflicts of interest to disclose Goals Promote
More informationAntipsychotic Prescription Pattern among Child and Adolescent Patients with Psychiatric Illnesses in Taiwan
222 Taiwanese Journal of Psychiatry (Taipei) Vol. 31 No. 3 2017 Original Article Antipsychotic Prescription Pattern among Child and Adolescent Patients with Psychiatric Illnesses in Taiwan Shu-Wen Cheng,
More informationPsychiatry in Primary Care: What is the Role of Pharmacist?
Psychiatry in Primary Care: What is the Role of Pharmacist? Benjamin Chavez, PharmD, BCPP, BCACP Clinical Associate Professor Director of Behavioral Health Pharmacy Services January 12, 2019 Disclosure
More informationDeveloping the Data Skills to Successfully Compete in Value Based Purchasing Models
Developing the Data Skills to Successfully Compete in Value Based Purchasing Models Presenters Chris Reist, M.D. Professor, Dept. of Psychiatry and Human Behavior, University of California at Irvine Expertise:
More informationPsychotropics and Foster Care: Challenge or Opportunity?
Psychotropics and Foster Care: Challenge or Opportunity? Raymond C. Love, PharmD, BCPP, FASHP Professor and Director, Mental Health Program University of Maryland School of Pharmacy Objectives At the conclusion
More informationPharmacy Prior Authorization GMH/SA and Non-Title 19/21 SMI Non-Formulary and Prior Authorization Guidelines
Non-Formulary Behavioral Health Medications ADHD medications for children under The patient must have a diagnosis for which the requested medication is: o Approved based on FDA indication and limits; OR
More informationSevere Mental Illness and Diabetes. Charlie Place
Severe Mental Illness and Diabetes Charlie Place Intro Me Community Mental Health Nurse Case manager for Assertive Outreach Team in Leeds Severe Mental Illness (SMI) usually diagnosis of schizophrenia
More informationNational Academy of Science July 17-18, 2018 Washington DC Larry Alphs, MD, PhD RESTRICTION OF TREATMENT QUALITY IN PRAGMATIC CLINICAL TRIALS
National Academy of Science July 17-18, 2018 Washington DC Larry Alphs, MD, PhD RESTRICTION OF TREATMENT QUALITY IN PRAGMATIC CLINICAL TRIALS Key Points for RWE in Randomized Clinical Trials What is the
More information2019 STEP THERAPY CRITERIA UCare Individual & Family Plans UCare Individual & Family Plans with Fairview
2019 STEP THERAPY CRITERIA UCare Individual & Family Plans UCare Individual & Family Plans with Fairview In some cases, UCare requires you to first try certain drugs to treat your medical condition before
More informationREXULTI (brexpiprazole) oral tablet
REXULTI (brexpiprazole) oral tablet Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit plan. This Pharmacy
More informationAnti-psychotic Polypharmacy in the Treatment of Patients with Resistant Schizophrenia: A Descriptive Study
Research Reviews: Pharmacy & Pharmaceutical Sciences e-issn: 2320-1215 www.rroij.com Anti-psychotic Polypharmacy in the Treatment of Patients with Resistant Schizophrenia: A Descriptive Study Etwal Bou
More informationESSENTIAL SHARED CARE AGREEMENT FOR Risperidone, Olanzapine, Quetiapine, Aripiprazole, Amisulpride or Asenapine
Ref No: E053 ESSENTIAL SHARED CARE AGREEMENT FOR Risperidone, Olanzapine, Quetiapine, Aripiprazole, Amisulpride or Asenapine NOTE: Please complete details on P1 &3 Send one copy to GP, Patient and file
More informationAntipsychotic Medications Age and Step Therapy
Market DC *- Florida Healthy Kids Antipsychotic Medications Age and Step Therapy Override(s) Approval Duration Prior Authorization 1 year Quantity Limit *Virginia Medicaid See State Specific Mandates *Indiana
More informationEvaluation of National Academic Detailing Service on Naloxone Kit Prescription Rates in the Veterans Health Administration
Evaluation of National Academic Detailing Service on Naloxone Kit Prescription Rates in the Veterans Health Administration Melissa LD Christopher, PharmD National Director Academic Detailing Program Office
More informationDrugs used in schizophrenia قادة فریق علم الا دویة : الشكر موصول لا عضاء الفریق المتمیزین :
MCQs SAQs Summar y Drugs used in schizophrenia قادة فریق علم الا دویة : لین التمیمي & عبدالرحمن ذكري الشكر موصول لا عضاء الفریق المتمیزین : روان سعد القحطاني فؤاد بھجت عبدالرحمن العریفي حاتم النداح pharma436@outlook.com
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE. Single Technology Appraisal
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE Single Technology Appraisal Aripiprazole for the treatment and prevention of acute manic and mixed episodes in bipolar disorder in children and adolescents
More informationCurrent Non-Preferred Agents
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35, Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More informationPotential control of antipsychotic-induced hyperprolactinemia and obesity in children and adolescents by aripiprazole
University of Wollongong Research Online Faculty of Science, Medicine and Health - Papers Faculty of Science, Medicine and Health 2010 Potential control of antipsychotic-induced hyperprolactinemia and
More informationAmy Edmondson Mulroy, MD
Curriculum Vitae Amy Edmondson Mulroy, MD 7940 Floyd Curl Drive, Suite 700 7940 Floyd Curl Drive, Suite 1020 San Antonio, Texas 78229 San Antonio, Texas 78229 EDUCATION 1997 General Adult Psychiatry Internship
More informationMedication Audit Checklist- Antipsychotics - Atypical
Medication Audit checklist Page 1 of 7 10-2018 Audit number: Client number: Ordering Provider: INDICATIONS 1) Disorders with psychotic symptoms (schizophrenia, schizoaffective disorder, manic disorders,
More informationANTIPSYCHOTIC POLYPHARMACY
Psychiatry and Addictions Case Conference UW Medicine Psychiatry and Behavioral Sciences ANTIPSYCHOTIC POLYPHARMACY RYAN KIMMEL, MD MEDICAL DIRECTOR HOSPITAL PSYCHIATRY UWMC GENERAL DISCLOSURES The University
More informationA Primer on Psychotropic Medications. Michael Flaum, MD
The Iowa Mental Health System and Employment for Individuals with Psychiatric Conditions Iowa Vocational Rehabilitation Services Conference Des Moines, IA, September 18, 2006 A Primer on Psychotropic Medications
More informationCHLORPROMAZINE EQUIVALENTS VERSUS DEFINED DAILY DOSES: HOW TO COMPARE ANTIPSYCHOTIC DRUG DOSES?
CHLORPROMAZINE EQUIVALENTS VERSUS DEFINED DAILY DOSES: HOW TO COMPARE ANTIPSYCHOTIC DRUG DOSES? C.A.W. Rijcken 1, T.B.M. Monster 1, J.R.B.J. Brouwers 1, L.T.W. de Jong van den Berg 1 1 Department of Social
More informationHOSPITAL BASED INPATIENT PSYCHIATRIC SERVICES (HBIPS) MEASURE SET
HOSPITAL BASED INPATIENT PSYCHIATRIC SERVICES (HBIPS) MEASURE SET Kathy Wonderly RN, MSEd, CPHQ Consultant Developed: February, 2013 Most recently revised: December 2018 The Psychiatric Measure Set CMS
More informationCardiometabolic Risk Factors and Antipsychotic Medications Changing Prescribing Practices Promoting Wellness
Cardiometabolic Risk Factors and Antipsychotic Medications Changing Prescribing Practices Promoting Wellness Sally Ricketts, M.D. New York State Office of Mental Health Bureau of Evidence-Based Services
More informationApplication for the Inclusion of New Medications for the WHO Formulary
17th Expert Committee on the Selection and Use of Essential Medicines Geneva, 2009 Application for the Inclusion of New Medications for the WHO Formulary 1. Summary Statement of the Proposal for Inclusion
More informationAntipsychotic Prescribing Audit:
Antipsychotic Prescribing Audit: Measuring the impact of a prescribing intervention Audit Co-ordinator/ Author of Report: Supervisor: Professor Shôn W Lewis Table of Contents List of Tables... 3 List of
More informationPsychopharmacological treatment of first episode psychosis
Psychopharmacological treatment of first episode psychosis Matcheri S Keshavan MD First episode Psychosis Treatment Assistance Center (FEP-TAC), Harvard Medical School, Beth Israel Deaconess Medical Center
More informationUniversity of Groningen. Pharmacy data as a tool for assessing antipsychotic drug use Rijcken, Claudia
University of Groningen Pharmacy data as a tool for assessing antipsychotic drug use Rijcken, Claudia IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to
More informationDepression. University of Illinois at Chicago College of Nursing
Depression University of Illinois at Chicago College of Nursing 1 Learning Objectives Upon completion of this session, participants will be better able to: 1. Recognize depression, its symptoms and behaviors
More informationMeasurement-based Scales in Major Depressive Disorder:
This program is paid for by Otsuka Pharmaceutical Development & Commercialization, Inc. and Lundbeck, LLC. The speaker is a paid contractor of Otsuka Pharmaceutical Development and Commercialization, Inc.
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Invega Sustenna, Invega Trinza) Reference Number: CP.PHAR.291 Effective Date: 12.01.16 Last Review Date: 08.18 Line of Business: Medicaid See Important Reminder at the end of this policy
More informationSTEP THERAPY CRITERIA
DRUG CLASS PRODUCTS) BRAND NAME (BRAND ONLY) (generic) STEP THERAPY CRITERIA ATYPICAL ANTIPSYCHOTICS (BRAND ONLY ABILIFY (AL TABLET & AL SOLUTION ONLY) (aripiprazole) FANAPT (BRAND ONLY) (iloperidone)
More informationSCCMHD: Quality Improvement Medication Monitoring Chart Review Summary Report Fiscal Year: , January to March
BACKGROUND Chart review is an integral part of Mental Health Department Quality Improvement Program and mandated for clients who are Medi-Cal beneficiaries. Quality Improvement Medication Monitoring Program
More informationMinimising the Impact of Medication on Physical Health in Schizophrenia
Minimising the Impact of Medication on Physical Health in Schizophrenia John Donoghue Liverpool Imagination is more important than knowledge Albert Einstein LIFESTYLE Making choices TREATMENT Worse Psychopathology,
More informationThe Comparison of the Effectiveness of Thiothixene and Risperidone as a Combination with Lithium for the Treatment of Patients with Bipolar Disorder
Zahedan Journal of Research in Medical Sciences Journal homepage: www.zjrms.ir The Comparison of the Effectiveness of Thiothixene and Risperidone as a Combination with Lithium for the Treatment of Patients
More informationPharmacy Benefit Management (PBM) Program FORMULARY/PRODUCT RESTRICTIONS
Workforce Safety & Insurance Revised Document Date: 07/21/2015 1600 E Century Ave Ste 1 PO Box 5585 Bismarck, ND 58506-5585 701.328.3800 1.800.777.5033 www.workforcesafety.com Pharmacy Benefit Management
More informationNetwork Meta-Analyses of Antipsychotics for Schizophrenia: Clinical Implications
Network Meta-Analyses of Antipsychotics for Schizophrenia: Clinical Implications JOHN M. DAVIS, MD Professor of Psychiatry University of Illinois at Chicago Chicago, Illinois and STEFAN LEUCHT, MD Klinik
More information